DE60024133D1 - Herstellungsverfahren auf industrieller basis von atorvastatin trihydrat hemi-kalziumsalz in kristalliner form - Google Patents

Herstellungsverfahren auf industrieller basis von atorvastatin trihydrat hemi-kalziumsalz in kristalliner form

Info

Publication number
DE60024133D1
DE60024133D1 DE60024133T DE60024133T DE60024133D1 DE 60024133 D1 DE60024133 D1 DE 60024133D1 DE 60024133 T DE60024133 T DE 60024133T DE 60024133 T DE60024133 T DE 60024133T DE 60024133 D1 DE60024133 D1 DE 60024133D1
Authority
DE
Germany
Prior art keywords
calcium salt
crystalline form
hemi calcium
based preparation
trihydrate hemi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60024133T
Other languages
English (en)
Other versions
DE60024133T2 (de
Inventor
William Tully
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Science and Technology Ireland Ltd
Original Assignee
Warner Lambert Research and Development Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11042528&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60024133(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Research and Development Ireland Ltd filed Critical Warner Lambert Research and Development Ireland Ltd
Application granted granted Critical
Publication of DE60024133D1 publication Critical patent/DE60024133D1/de
Publication of DE60024133T2 publication Critical patent/DE60024133T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE60024133T 1999-12-17 2000-12-18 Herstellungsverfahren auf industrieller basis von atorvastatin trihydrat hemi-kalziumsalz in kristalliner form Expired - Fee Related DE60024133T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IE9900132 1999-12-17
WOPCT/IE99/00132 1999-12-17
PCT/IE2000/000150 WO2001044180A1 (en) 1999-12-17 2000-12-18 A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium salt

Publications (2)

Publication Number Publication Date
DE60024133D1 true DE60024133D1 (de) 2005-12-22
DE60024133T2 DE60024133T2 (de) 2006-08-03

Family

ID=11042528

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60024133T Expired - Fee Related DE60024133T2 (de) 1999-12-17 2000-12-18 Herstellungsverfahren auf industrieller basis von atorvastatin trihydrat hemi-kalziumsalz in kristalliner form

Country Status (13)

Country Link
US (1) US6600051B2 (de)
EP (2) EP1237865B1 (de)
JP (1) JP2003517038A (de)
AT (1) ATE309985T1 (de)
AU (1) AU776613B2 (de)
CA (1) CA2388226A1 (de)
DE (1) DE60024133T2 (de)
ES (1) ES2252088T3 (de)
HU (1) HUP0203708A3 (de)
IL (2) IL149087A0 (de)
MX (1) MXPA02004078A (de)
WO (1) WO2001044180A1 (de)
ZA (1) ZA200203648B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1148049E (pt) 1995-07-17 2005-02-28 Warner Lambert Co Formas cristalinas de hemi-sal de calcio do acido [r-(r*,r*)]-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)-carbonil)-1h-pirrole-1-heptanoico (atorvastatina)
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
CA2450111C (en) * 2001-06-29 2006-02-07 Warner-Lambert Company Llc Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin)
US7074818B2 (en) * 2001-07-30 2006-07-11 Dr. Reddy's Laboratories Limited Crystalline forms VI and VII of Atorvastatin calcium
US20060020137A1 (en) * 2001-11-29 2006-01-26 Limor Tessler Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
MXPA04007939A (es) * 2002-02-15 2004-11-26 Teva Pharma Formas cristalinas novedosas de hemi-calcio de atorvastatina y procesos para su preparacion; procesos novedosos para la preparacion de hemi-calcio de atorvastatina en sus formas i, viii i ix.
CN100379723C (zh) 2002-02-19 2008-04-09 特瓦制药工业有限公司 阿托伐他汀半钙脱溶剂的方法和基本上不含有机溶剂的阿托伐他汀半钙
WO2004050618A2 (en) * 2002-11-28 2004-06-17 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
EP1424324A1 (de) * 2002-11-28 2004-06-02 Teva Pharmaceutical Industries Limited Kristalline Form F von Atorvastatin
ES2739493T3 (es) 2004-05-05 2020-01-31 Pfizer Prod Inc Formas de sal de de atorvastatina con benetamina
ES2586561T3 (es) * 2004-07-16 2016-10-17 Lek Pharmaceuticals D.D. Productos de degradación oxidativa de atorvastatina calcio
TW200745026A (en) * 2005-12-13 2007-12-16 Teva Pharma Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
US8486500B2 (en) * 2007-06-20 2013-07-16 Coating Excellence International Llc Flat bottom bag
GR1006173B (el) * 2007-12-21 2008-11-26 Ανωνυμος Φαρμακευτικη-Χημικη Βιομηχανια Medichromα.Ε. Χημικη συνθεση του (3r, 5r) - διυδροξυ - 7 - [2-(4-φθοροφαινυλ) - 5 - σοπροπυλ - 3 - φαινυλ - 4 - φαινυλκαρβαμοϋλο - πυρρολυλο - τριενυδρο - επτανοϊκου ασβεστιου, εφαρμογη φαρμακευτικου σκευασματος και παραγωγικη διαδικασια
CN103483238B (zh) * 2013-08-20 2014-12-31 蚌埠丰原医药科技发展有限公司 阿托伐他汀钙三水合物的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
PT1148049E (pt) * 1995-07-17 2005-02-28 Warner Lambert Co Formas cristalinas de hemi-sal de calcio do acido [r-(r*,r*)]-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)-carbonil)-1h-pirrole-1-heptanoico (atorvastatina)
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
CN1093126C (zh) 1996-07-29 2002-10-23 沃尼尔·朗伯公司 合成被保护的(s)-3,4-二羟基丁酸酯的改进方法
AU755543B2 (en) 1997-12-19 2002-12-12 Warner-Lambert Export Limited Process for the synthesis of 1,3-diols

Also Published As

Publication number Publication date
AU776613B2 (en) 2004-09-16
US20020156294A1 (en) 2002-10-24
EP1237865A1 (de) 2002-09-11
WO2001044180A1 (en) 2001-06-21
MXPA02004078A (es) 2002-10-11
ES2252088T3 (es) 2006-05-16
EP1237865B1 (de) 2005-11-16
ZA200203648B (en) 2003-02-10
CA2388226A1 (en) 2001-06-21
DE60024133T2 (de) 2006-08-03
US6600051B2 (en) 2003-07-29
EP1584616A1 (de) 2005-10-12
AU2544001A (en) 2001-06-25
IL149087A (en) 2006-12-31
JP2003517038A (ja) 2003-05-20
HUP0203708A3 (en) 2003-11-28
IL149087A0 (en) 2002-11-10
ATE309985T1 (de) 2005-12-15
HUP0203708A2 (hu) 2003-03-28

Similar Documents

Publication Publication Date Title
DE60024133D1 (de) Herstellungsverfahren auf industrieller basis von atorvastatin trihydrat hemi-kalziumsalz in kristalliner form
PE20030124A1 (es) FORMAS CRISTALINAS DE LA SAL DE CALCIO DEL ACIDO[R-(R*,R*)]-2-(4-FLUOROFENIL)-ß,d- DIHIDROXI-5-(1-METILETIL)-3-FENIL-4-[(FENILAMINO)CARBONIL]-1H-PIRROL-1-HEPTANOICO
AU8691691A (en) Mineral wool products for the cultivation of plants
ATE80129T1 (de) Verfahren zur herstellung von synthetischen calciumsilicaten und ihre verwendungen.
HU9402600D0 (en) Halichondrins and related compounds
MY109772A (en) Fermentation product induced from poultry manure
DE69228727T2 (de) Verfahren zur Herstellung von gewissen Biphenyltetrazolderivaten
HUP0203798A2 (hu) Eljárás kristályos atorvastatin-kalcium előállítására
DE60113243D1 (de) Neue kristalline form eines pyrrolidylthiocarbapenem-derivates
DE69028570T2 (de) Verfahren zur Herstellung einer säureaktivierten Bleicherde
ATE165357T1 (de) Neue verwendung bis-heterocyclische verbindungen und dessen zusammensetzungen
ES2184254T3 (es) Metodo para producir borato de calcio.
AU2003266261A1 (en) Process for preparing nitrooxyalkyl substituted esters of carboxylic acids, intermediates useful in said process and preparation thereof
DE69618806T2 (de) Verfahren zur herstellung von calciumborat
HUT60483A (en) Process for producing homoserine lactones
DE50113398D1 (de) Verfahren zur herstellung von n-methyl-n'-nitroguanidin
ATE138628T1 (de) Kultursubstrate auf der basis von torf
AU2818589A (en) Use of calcium sulphate to improve the fermentation of organic fertilizers
JPH048234A (ja) 植物栽培容器
JP2000342073A (ja) コルク植木鉢
KR960029286A (ko) 인공점토의 합성방법
KR970026901A (ko) 졸-겔법을 이용한 수산화아파타이트의 제조방법
DE59308818D1 (de) Verfahren zur Herstellung von Trimethylaluminium durch Reaktion von Methylaluminiumchloriden mit Natrium in Feststoffreaktoren
RU2001106982A (ru) Способ получения левулиновой кислоты
ES2019039A6 (es) Pintura para techos y paredes y procedimiento para su elaboracion.

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee